The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Challenges in implementing first-line triplet therapies in patients with HCC
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses challenges in implementing first-line triplet therapies for hepatocellular carcinoma (HCC). The main challenge arises from the fact that 80 to 90% of HCC patients also have liver cirrhosis, increasing the risk of high toxicity or intolerable side effects. While some Phase I trial data suggests that triple combinations are feasible, caution is essential due to the potential safety concerns associated with administering three drugs simultaneously in this patient population. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
